Ensign Peak Advisors
ENTA icon

Ensign Peak Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Ensign Peak Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,250
Closed -$226K – 1746
2023
Q3 		$226K Buy
20,250
+4,800
+31% +$77.3K ﹤0.01% 1721
2023
Q2 		$331K Hold
15,450
– – ﹤0.01% 1705
2023
Q1 		$625K Buy
15,450
+250
+2% +$11.9K ﹤0.01% 1568
2022
Q4 		$707K Sell
15,200
-20,070
-57% -$915K ﹤0.01% 1445
2022
Q3 		$1.83M Buy
35,270
+1,186
+3% +$69.3K ﹤0.01% 815
2022
Q2 		$1.61M Sell
34,084
-4,011
-11% -$218K ﹤0.01% 895
2022
Q1 		$2.71M Hold
38,095
– – 0.01% 769
2021
Q4 		$2.85M Buy
38,095
+17,195
+82% +$1.35M 0.01% 835
2021
Q3 		$1.19M Hold
20,900
– – ﹤0.01% 1371
2021
Q2 		$920K Buy
20,900
+500
+2% +$24.5K ﹤0.01% 1464
2021
Q1 		$1.01M Buy
20,400
+3,500
+21% +$175K ﹤0.01% 1426
2020
Q4 		$711K Hold
16,900
– – ﹤0.01% 1518
2020
Q3 		$774K Hold
16,900
– – ﹤0.01% 1414
2020
Q2 		$849K Hold
16,900
– – ﹤0.01% 1329
2020
Q1 		$869K Buy
16,900
+2,000
+13% +$107K ﹤0.01% 1223
2019
Q4 		$921K Buy
+14,900
New +$924K ﹤0.01% 1362

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ensign Peak Advisors's ENTA Position: Q4 2023 in Review

Ensign Peak Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 20,250 shares — an estimated $226K sold.

Ensign Peak Advisors first reported a position in ENTA in Q4 2019 and held it in 16 quarters. The position peaked at $2.85M in Q4 2021. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Ensign Peak Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 20,250 Enanta Pharmaceuticals shares in Q4 2023, an estimated $226K.
  • Ensign Peak Advisors first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 16 quarters.
  • Ensign Peak Advisors's Enanta Pharmaceuticals position peaked at $2.85M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.